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Abstract 
Background: In patients with hematological malignancies and acute respiratory failure (ARF), noninvasive ventilation 
was associated with a decreased mortality in older studies. However, mortality of intubated patients decreased in the 
last years. In this study, we assess outcomes in those patients according to the initial ventilation strategy.
Methods: We performed a post hoc analysis of a prospective multicentre study of critically ill hematology patients, in 
17 intensive care units in France and Belgium. Patients with hematological malignancies admitted for ARF in 2010 and 
2011 and who were not intubated at admission were included in the study. A propensity score‑based approach was 
used to assess the impact of NIV compared to oxygen only on hospital mortality.
Results: Among 1011 patients admitted to ICU during the study period, 380 met inclusion criteria. Underlying 
diseases included lymphoid (n = 162, 42.6 %) or myeloid (n = 141, 37.1 %) diseases. ARF etiologies were pulmonary 
infections (n = 161, 43 %), malignant infiltration (n = 65, 17 %) or cardiac pulmonary edema (n = 40, 10 %). Mechani‑
cal ventilation was ultimately needed in 94 (24.7 %) patients, within 3 [2–5] days of ICU admission. Hospital mortality 
was 32 % (123 deaths). At ICU admission, 142 patients received first‑line noninvasive ventilation (NIV), whereas 238 
received oxygen only. Fifty‑five patients in each group (NIV or oxygen only) were matched according the propensity 
score. NIV was not associated with decreased hospital mortality [OR 1.5 (0.62–3.65)].
Conclusions: In hematology patients with acute respiratory failure, initial treatment with NIV did not improve sur‑
vival compared to oxygen only.
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Background
Acute respiratory failure (ARF) remains the first rea-
son for admission to ICU in patient with hematologi-
cal disease [1–3]. Various etiologies lead to ARF in that 
setting. Among the determinants of mortality in hema-
tology patients with ARF, mechanical ventilation remains 
the major determinant of death [1, 4], as well as the type 
of ARF etiology (e.g., Invasive aspergillosis) [1, 5], poor 
performance status, allogeneic bone marrow stem cell 
transplantation, delayed ICU admission [6] or associated 
organ dysfunction [1, 3, 7]. Fifteen to 20 years ago, hema-
tology patients with acute respiratory failure exhibited 
mortality rates of about 50 % [7–11], and for those who 
needed mechanical ventilation mortality reached 90  % 
[8, 12]. At that time, studies reported significant survival 
benefits from noninvasive ventilation [9, 12], even though 
delayed intubation after NIV failure was associated with 
higher mortality [11, 13]. In that setting, noninvasive 
ventilation (NIV) was an efficient alternative to invasive 
mechanical ventilation (iMV). In 2001, a randomized 
controlled trial of NIV versus oxygen in 52 immunocom-
promised reported a significantly decreased mortality 
when NIV was applied [12]. In that study, mortality of 
cancer patients with acute respiratory failure not receiv-
ing NIV was 93 %. Another study in post-operative solid 
organ transplant patients also reported survival benefits 
from early NIV [14]. However, more recently, non-rand-
omized studies failed to confirm these results [15]. Over 
the last two decades, survival of patients with hemato-
logical malignancy admitted to ICU improved, even for 
patients receiving mechanical ventilation [16–19]. For 
instance, in a recent study from our GRRROH network, 
mortality of hematology patients requiring mechanical 
ventilation and who had at least one additional organ 
dysfunction was 60  % [1]. Similar results were reported 
by others [20, 21]. Also, survival in cancer patients with 
ARDS increased from 18 to 48  % over the last 20  years 
[4]. Therefore, survival benefits from NIV could either 
be harder to demonstrate or may have been balanced by 
improvements in the way mechanical ventilation is deliv-
ered [22, 23]. Hence, to appraise the literature with more 
recent prospective multicenter data, we assessed the 
impact of NIV use on mortality in a cohort of hematol-




This study is a post hoc analysis of a prospective 
cohort of 1011 patients admitted to ICU with hemato-
logical malignancy [1]. This cohort was prospectively 
recruited between 01/2010 and 05/2011 from 17 ICUs 
in France and Belgium. All patients with hematological 
malignancies admitted to ICU were included in the 
cohort and data were prospectively collected every day 
from admission to day 28. Data reported in tables and 
figures were collected prospectively by study investiga-
tors. Hospital mortality was available for all the patients.
Selection of the study population
Among the 1011 hematology patients, those admitted 
with ARF were included in the present analysis. Inclu-
sion criteria were presence of ARF as defined by tachyp-
nea >30/min, respiratory distress, SpO2 <90 at admission 
and labored breathing. Exclusion criteria were mechani-
cal ventilation at admission.
Variables of interest
Underlying disease, performance status in the 3 months 
from ICU admission, malignancy status (remission or 
not), ARF etiology, severity of organ dysfunction were the 
variables of interest as the primary study identified those 
as independently associated with hospital mortality [1].
Using pre-established diagnostic criteria [24], three 
independent investigators analyzed the charts to classify 
patients as having pulmonary infection, cardiac pulmo-
nary edema, pulmonary infiltration by the malignancy, 
or other ARF etiologies. Patients were deemed to have an 
undetermined ARF etiology when no cause of ARF could 
be clinically or microbiologically documented [24].
Statistical analyses
All data are presented as medians (25th–75th percentiles) 
for quantitative variables and frequencies (percentage) 
for qualitative variables. Organ dysfunction was assessed 
by dichotomizing the LOD score at day 1 (LOD  =  0 
or LOD  >  0). Baseline characteristics were compared 
between survival and dead patients using Wilcoxon rank-
sum test for quantitative variables and Fisher’s exact test 
for qualitative variable.
A propensity score-based approach was used to limit 
bias of between-group comparison to assess the impact 
of NIV compared to oxygen only on hospital mortality 
[25]. The propensity score was defined as the probabil-
ity that a patient with specific baseline characteristics 
receives NIV trial. Then, two patients with identical pro-
pensity score value but in the two different treatment 
groups (NIV versus oxygen only) can be considered as 
comparable, and matching on the propensity score has 
been shown as one of the most efficient methods for 
treatment effect assessment [26, 27]. We computed the 
propensity score using logistic regression to predict NIV 
O2 group based on baseline characteristics known to 
be linked to the mortality [2] (underlying hematologi-
cal disease, performances status over 2, delay between 
hospital admission and ICU admission, delay since the 
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diagnosis, complete or partial remission, allogenic stem 
cell transplantation, admission from ICU) or with a 
standardized difference above 0.1 (age over 60  years, 
gender, neutropenia, etiology of acute respiratory failure, 
respiratory SOFA score over 3, kidney SOFA score over 
3, hemodynamic SOFA score over 3, SOFA score at day 
1 over 7, maximal respiratory rate) [1, 26, 28]. Standard-
ized differences are used to compare balance in baseline 
covariates between two Oxygen and NIV groups [29]. 
A 1:1 matching algorithm without replacement was 
used within a given range of 0.20 standard deviations 
of the logit of the estimated propensity score [13]. Final 
analyses on the matched dataset were performed using 
a logistic regression with a random effect on the paired 
observations except for the length of stay analyzed with 
a Cox random effect model. Results were presented as 
Odds-Ratio (OR) with their 95  % CI. Finally, we per-
formed a sensitivity analysis using the inverse probabil-
ity weighting (IPW) approach to estimate the treatment 
effect. This approach consists in using weights based 
on the propensity score to create a synthetic sample in 
which the distribution of measured baseline covariates 
is independent of treatment assignment. All tests were 
two-sided at the 0.05 significance level. Analyses were 
performed using R statistical package (online at http://
www.R-project.org).
Results
Among 1011 patients included in the primary study, 
380 were admitted for respiratory symptom and were 
not requiring mechanical ventilation at ICU admission 
(Fig.  1). As shown in Table  1, performance status was 
0–1 for 308 patients (81  %), the malignancy was active 
(ongoing/recent chemotherapy) in 265 patients (72.8  %) 
and 112 (29.4 %) patients were neutropenic at admission. 
Also, 74 (19.5 %) patients underwent allogeneic stem cell 
transplantation. ICU admission occurred 5 (0–20) days 
after hospital admission and 90 (23.7  %) patients were 
admitted from the emergency department.
Underlying diseases were acute myeloid leukemia 
(n = 112, 29.5 %), acute lymphoid leukemia (n = 28, 7 %), 
lymphoma (n = 108, 28.4 %), myeloma (n = 54, 14.2 %), 
or chronic malignancies (n  =  78, 20.5  %). ARF etiolo-
gies included infection (n = 161, 42.4 %), cardiac pulmo-
nary edema (n =  43, 11.3  %), pulmonary infiltration by 
the malignancy (n = 65, 17.1 %). No diagnosis was found 
for 94 (24.7 %) patients and 17 (4.4 %) patients had other 
miscellaneous diagnosis.
During the first 2 days, 238 (62.6 %) patients received 
oxygen only and 142 (37.1  %) patients received NIV. 
Hospital mortality was 32.4 % (n = 123) and was higher 
in the NIV group (44 versus 26  % in the oxygen group, 
Table 1). Overall intubation rate was 24.7 % (94 patients). 
Fig. 1 Flow chart. ICU intensive care medicine, ARF acute respiratory failure, NIV noninvasive ventilation, iMV invasive mechanical ventilation
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Table 1 Characteristics of patients admitted with ARF according to initial ventilator strategy
All data are presented as medians [25th–75th percentiles] for quantitative variables and frequencies (percentage) for qualitative variables. Comparisons between the 
two groups were performed with Chi-square test for qualitative value and Wilcoxon test for quantitative value
SOFA score Sequential Organ Failure Assessment score
a Other included undetermined diagnosis (n = 94, 84.6 % of other diagnosis)
Variables Patients receiving  
oxygen only (n = 238)




 Age (year) m, [IQR] 60 [49–67] 60 [50–70] 0.15 0.14
 Gender male 102 (42) 57 (40) 0.67 0.06
 Underlying disease 0.27
  Myeloid disease 84 (35) 57 (40) 0.10
  Lymphoid disease 109 (46) 53 (37) 0.17
  Other 45 (19) 32 (22) 0.09
 Delay from diagnosis to ICU admission
  Newly diagnosed 85 (36) 30 (21)
  Remission 58 (24) 41 (29) 0.05
  No remission 91 (38) 41 (29)
 Allogenic stem cell transplantation 41 (17) 33 (23) 0.18 0.15
 Performance status >2 (severely disabled  
or bedridden)
36 (15) 36 (25) 0.015 0.26
 Charlson comorbidity score 4 [2–5] 4 [3–5] 0.73 0.03
 Delay from hospital to ICU admission (days) 4 [0–19] 7 [1–21] 0.29 0.13
 Admission from emergency department 61 (26) 29 (20) 0.26 0.12
 Neutropenia at admission 65 (27) 47 (33) 0.25 0.13
 ARF etiology 0.20
  Infection 104 (43) 57 (40) 0.07
  Cardiogenic edema 21 (9) 22 (15) 0.20
  Malignant Infiltration 39 (16) 26 (18) 0.05
  Othera 74 (31) 37 (26) 0.11
 Maximum respiratory rate at day 1 31 [25–36] 35 [30–41] <0.001 0.57
 Shock at day 1 40 (17) 23 (16) 1 0.02
 Acute kidney injury at day 1 40 (17) 23 (16) 1 0.02
 SOFA score at day 1 > 7 34 (15) 47 (36) <0.001 0.51
 Do not intubate order day 1 or day 2 7 (2.9) 8 (5.6) 0.23 0.09
VNI parameters
 Number of trial/day (day1) 2.5 (2–4)
 Number of trial/day (day2) 2 (2–5)
 Length of NIV (h) (day 1) 4 (2–8)
 Length of NIV (h) (day 2) 5 (3–9)
 Respiratory rate under NIV at day 1 26 (20–32)
 Pressure support day 1 (cm H2O) 10 (8–12.7)
 Pressure support day 2 (cm H2O) 10 (8–14)
 PEEP at day 1 (cm H2O) 5 (5–7)
 PEEP at day 2 (cm H2O) 5 (5–6)
Outcome
 Intubation throughout the ICU stay 48 (20) 46 (32) 0.01
 Time from admission to intubation 3 [2–5] 3 [2–5] 0.85
 ICU length of stay 5 [2–9] 7 [4–20] <0.001
 ICU‑acquired infection 27 (11) 21 (15) 0.34
 Hospital mortality 61 (26) 62 (44) <0.001
 Hospital mortality of intubated patients 27/48 (56) 35/46 (76) 0.05
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Intubation was needed in 46 (32.4  %) patients from the 
NIV group and 48 (20.2  %) patients from the oxygen 
group. Table  1 describes time between ICU admission 
and intubation, ICU length of stay and ICU-acquired 
infection rate in the NIV group and in the oxygen group. 
In the NIV group, 8 (5.6  %) patients received high flow 
nasal cannula between NIV sessions. In the oxygen 
group, 7 (2.9 %) received high flow nasal cannula.
Patient’s characteristics are reported in Table  2. NIV 
parameters are described in Tables 1 and 3.
One hundred ten patients (55 patients in each group) 
were included in the propensity score (Table  3). Impact 
of NIV was not different in the matched population for 
hospital mortality (p = 0.37) intubation rate (p = 0.67), 
ICU length of stay (p  =  0.47), ICU-acquired infection 
rate (p =  0.59) (Table 3). Odd ratio of mortality associ-
ated with NIV was 1.50 (0.62–3.65) (p = 0.37). A sensitiv-
ity analysis conducted with inverse probability weighting 
approach for propensity score analysis which considers 
the entire group of 380 patients led to similar conclusions 
[OR 1.05 (0.49–2.26), p = 0.89]. Also, we performed the 
same matching analysis without patient with ARF related 
to cardiogenic edema and odd ratio was 1.88 (0.71–5.00), 
p = 0.50.
Table 2 Patient’s characteristics according to hospital survival status
All data are presented as medians [25th–75th percentiles] for quantitative variables and frequencies (percentage) for qualitative variables. Comparisons between the 
two groups were performed with Chi-square test for qualitative value and Wilcoxon test for quantitative value
iMV invasive mechanical ventilation, SOFA score Sequential Organ Failure Assessment score
a Other included undetermined diagnosis (n = 94, 84 %)
Variables Alive at hospital  
discharge (n = 257)




 Age (year) m, [IQR] 60 [50–68] 60 [49.5–68.5] 0.91
 Gender male (%) 108 (42) 51 (41) 1
 Underlying malignancy 0.61
  Myeloid disease 92 (35.8) 49 (39.8)
  Lymphoid disease 114 (44.4) 48 (39)
  Other 52 (19.8) 26 (21.1)
 Disease status at ICU admission 0.93
  Newly diagnosed 83 (32.4) 32 (26.2)
  Remission 68 (26.6) 31 (25.4)
  No remission 104 (40.6) 55 (45.1)
 Allogeneic stem cell transplantation 37 (14.4) 37 (30.3) 0.0005
 Performance status >2 (severely disabled or bedridden) 39 (14.8) 34 (27.6) 0.005
 Charlson comorbidity score 4 [2–5] 3 [3–5] 0.9
 Time (days) from hospital to ICU admission 3 [0–16] 12 [2–24.2] <0.001
 Admission from emergency department 72 (28) 18 (14.6) 0.004
 Neutropenia at ICU admission 65 (25.3) 47 (38.2) 0.01
 ARF etiology 0.49
  Infection 115 (44.7) 46 (37.4)
  Cardiogenic edema 29 (11.3) 14 (11.4)
  Malignant Infiltration 40 (15.6) 25 (20.3)
  Othera 73 (28.4) 38 (30.9)
 Maximum respiratory rate at day 1 (/min) 32 [26–37] 33.5 [29–40] 0.026
 Noninvasive ventilation at day 1 or 2 80 (31.1) 62 (50.4) 0.0004
 Shock at day 1 44 (17.1) 19 (15.4) 0.77
 Acute kidney injury at day 1 44 (17.1) 6 [4–8] 0.77
 SOFA score at day 1 > 7 44 (18) 37 (33) 0.003
Outcome
 Intubation throughout the ICU stay 32 (12.4) 62 (50.4) <0.001
 Time from admission to intubation 4 [2–5] 3 [2–5] 0.77
 ICU length of stay 5 [3–7] 7 [3–15] <0.001
 ICU‑acquired infection 17 (7) 31 (25) <0.001
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Discussion
Acute respiratory failure is the leading cause for ICU 
admission in patients with hematological malignancies. 
Mortality of patients requiring mechanical ventilation 
remains high so that every strategy that avoids intu-
bation should be given priority. Previous studies have 
demonstrated benefit from early NIV in immunocom-
promised patients with acute respiratory failure [12] 
Table 3 Characteristics of patients matched based on the propensity score
All data are presented as medians [25th–75th percentiles] for quantitative variables and frequencies (percentage) for qualitative variables
Matching criteria were based on baseline characteristics known to be linked to the mortality or with a standardized difference above 0.1
a Other included undetermined diagnosis
Variables Oxygen therapy (n = 55) NIV therapy (n = 55) Std diff
Baseline characteristics
 Age (year) m, [IQR] 60 [47–67] 61 [49.5–68] 0.05
 Gender male (%) 23 (41.8) 20 (36.6) 0.11
 Underlying malignancy
  Myeloid disease 27 (49) 22 (40) 0.18
  Lymphoid disease 18 (32.7) 19 (34.5) 0.04
  Other 10 (18.1) 14 (25.4) 0.17
 Remission 16 (29) 18 (32.7) 0.08
 Allogeneic stem cell transplantation 10 (18.8) 10 (18.8) 0
 Performance status >2 (severely disabled or bedridden) 12 (21.8) 11 (20) 0.04
 Charlson comorbidity score 4 [3–6] 4 [3–5] 0.01
 Time (days) from hospital to ICU admission 4 [0–15] 6 [0–13.5] 0.02
 Admission from emergency department 39 (71) 40 (72.7) 0.04
 Neutropenia at ICU admission 39 (71) 37 (67.3) 0.08
 ARF etiology
  Infection 20 (36.4) 20 (36.4) 0
  Cardiogenic edema 10 (18.2) 8 (14.5) 0.09
  Malignant Infiltration 13 (23.6) 12 (21.8) 0.04
  Othera 12 (21.8) 15 (27.3) 0.13
 Maximum respiratory rate at day 1/min 33 [26.5–38.5] 32 [29–41] 0.14
 Shock at day 1 9 (16.4) 9 (16.4) 0
 Acute kidney injury at day 1 9 (16.4) 9 (16.4) 0
 SOFA score at day 1 > 7 15 (27.3) 15 (27.3) 0
 Do not intubate order day 1 or day 2 0 (0) 2 (3.6) 0.27
VNI parameters
 Number of trial/day (day 1) 3 (2–5)
 Number of trial/day (day 2) 3.5 (1–5.2)
 Length of NIV (hours) (day 1) 6.2 (3–9)
 Length of NIV (hours) (day 2) 5.5 (3–9)
 Respiratory rate under NIV at day 1 26.5 (21.5–32.5)
 Pressure support day 1 (cm H2O) 10 (8–13)
 Pressure support day 2 (cm H2O) 11.5 (8.5–14)
 PEEP at day 1 (cm H2O) 6 (5–7)
 PEEP at day 2 (cm H2O) 5 (5–7)
Outcome
 Intubation throughout the ICU stay 14 (25.4) 16 (29.1)
 Time from admission to intubation 4 [2–6] 3 [2–5]
 Length of ICU stay 5 [3–11] 6 [4–14]
 ICU‑acquired infection 5 (9) 6 (11)
 Hospital mortality 11 (20) 15 (27.3)
 Mortality of intubated patients 5/14 (36) 7/16 (44)
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or in post-operative respiratory distress in solid organ 
transplants [14]. However, at that time, intubation and 
mortality rates of patients treated in the control group 
were high as this occurred prior to recent advances in 
outcomes [17–19]. In this study where overall intubation 
and mortality rates were 24.7 and 32.4  %, respectively, 
noninvasive ventilation did not reduce hospital mortal-
ity and did not reduce intubation rates. These findings 
are in agreement with recently published data [12, 14, 
15]. They also raise concern about the place dedicated to 
NIV in hematology patients. As this study did not report 
any harm from NIV, clinicians should apply NIV as they 
are used to do, until the results of a trial of NIV versus 
oxygen become available. NIV remains then the gold 
standard for the initial ventilatory strategy in hematologi-
cal patient. However, clinicians should be aware that as 
mortality rates have dramatically decreased over the last 
two decades, hematology patients with acute hypoxemic 
respiratory failure should be managed as are managed all 
other patients.
Interestingly, patients managed in this study had simi-
lar severity at ICU admission than those admitted in 
other studies [1, 21, 30], but their intubation rate was 
only 24.7  %, compared to the 40  % previously reported. 
Early admission may explain some of these differences as 
patients in the present cohort were admitted 5 (0–20) days 
after hospital admission, earlier than in previous stud-
ies. Therefore, it is another indirect association between 
early admission and improved outcomes [6, 31]. A trial of 
early ICU admission remains, however, warranted. Along 
this line, the low mortality rate reported in this study in 
ARF patient not intubated offers opportunities for further 
improving outcomes in this high-risk group.
Over the last decade, mortality of patients with hema-
tological malignancy receiving mechanical ventilation 
has decreased to reach a plateau of 50–60 % [1, 20]. In 
that context, NIV failure has been associated with higher 
mortality [7, 30]. Delayed admission to the ICU in 
hematology patients with ARF was also associated with 
high mortality in recent studies [6, 32]. In the present 
study, propensity score analysis in matched population 
reported that NIV use was not associated with changes 
in mortality rates or in any secondary endpoint. In this 
study, the 32 % mortality rate was relatively low. This dif-
ference could be explained by the matching approach 
having selected observations on their propensity score 
to receive NIV or oxygen therapy only. Therefore, com-
pared to previous studies, patients with associated organ 
dysfunction or with need for rapid intubation were 
excluded, even though they were maintained in other 
studies. However, we also performed an analysis based 
on inverse probability weighting. In this analysis, all 
patients were included and the results were not differ-
ent. Again, we argue that low mortality rates in our study 
were related to early admission to the ICU as well as to 
recent improvements in the management of hematol-
ogy patients in the ICU. ARF etiology has been shown 
as a main determinant of outcomes [5, 7]. In the pre-
sent study, ARF etiology was included in the matching 
criteria. In that setting, patients likely to have cardiac 
pulmonary edema would have received more NIV and 
their outcomes would have been better than patients 
with other ARF etiologies. However, we performed the 
analysis without patients with ARF related to cardio-
genic edema and conclusion was not different. However, 
herein, most of ARF were related to infections a condi-
tion that has not been reported to be improved by NIV. 
Similarly, based on the Charlson comorbidity score, very 
few patients had COPD and none of them were hyper-
capnic, another situation where NIV should not be dis-
cussed. Most of patients in this study were intubated 
within the first days of admission.
This study had several limitations. First, this was an 
analysis of a cohort and not a randomized trial aimed to 
demonstrate benefit from NIV in hematology patients 
with ARF. Although we performed an analysis based on 
a propensity score, the results of such trial remain war-
ranted. Second, the decision to offer NIV to ARF patients 
was left to physician in charge. Even though centers par-
ticipating to this study have large experience of dealing 
with hematology patients, no NIV protocol was applied 
in this study. Third, only 110 patients were included in the 
propensity analysis. Only one-third of the cohort could 
be included in the propensity score and is related to dif-
ferent population at baseline. NIV sessions would be pre-
scribed for the most severe patients as shown in Table 1. 
Maximum respiratory rate at day 1 and SOFA score  >7 
at day 1 were higher in NIV. Although this sample could 
be seen as small, it allowed a pseudo-randomisation (in 
a homogeneous sample) including far more patients than 
in the 15-year-old studies that demonstrated benefits 
from NIV. In observational studies, propensity analysis 
with such a matching procedure ensures to be as close as 
possible to a randomized clinical trial by selecting patient 
with comparable characteristics. The result of a sensitiv-
ity analysis conducted with inverse probability weighting 
approach for propensity score analysis which considers 
the entire group of 380 patients gave a quite different 
result [OR 1.05 (0.49–2.26) versus 1.50 (0.62–3.65)], but 
led to similar conclusion. A trial to demonstrate survival 
benefits from NIV would require the inclusion of at least 
300 patients (150 in each group) based on mortality rates 
reported in this study and in the most recent papers of 
the literature.
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Conclusion
This study demonstrated no benefit from NIV in a cohort 
of patients with hematological malignancies admitted 
to the ICU for acute respiratory failure. The propen-
sity analysis as well as the inverse probability weight-
ing approach suggests that few biases explain this lack 
of benefit. A trial of early NIV in immunocompromised 
patients with acute respiratory failure is warranted. Until 
the results of such trial, clinicians should not deprive 
hematology patients from early intubation and optimal 
ventilation [33].
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